Macromolecular microparticles and methods of production

• US 5,578,709 A
• Filed: 03/04/1994
• Issued: 11/26/1996
• Est. Priority Date: 03/09/1993
• Status: Expired due to Term

• Current Assignee: Baxter Healthcare SA (Baxter International Inc.), Baxter International Inc.
• Original Assignee: Epic Therapeutics, Inc. (Baxter International Inc.)
• Inventors: Woiszwillo, James E.
• Primary Examiner(s): LeGuyader, John L.
• Assistant Examiner(s): DEGEN, NANCY JILL
• Application Number:
  US08/206,456
• Time in Patent Office: 998 Days
• Field of Search: 530/350, 530/402, 530/409, 530/410, 530/810, 530/811, 530/812, 530/813, 436/518, 436/523, 436/528, 436/529, 436/535
• US Class Current: 530/410
• CPC Class Codes: A61K 47/6927 the form being a solid microparticle having no hollow or gas-filled cores
• CPC Class Codes: A61K 9/1658 Proteins, e.g. albumin, gelatin
• CPC Class Codes: A61K 9/1694 resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: G01N 33/54313 the carrier being characterised by its particulate form
• CPC Class Codes: G01N 33/54326 Magnetic particles
• CPC Class Codes: Y10S 530/812 Peptides or proteins is immobilized on, or in, an organic carrier

Abstract

A macromolecular microparticle composition formed by dehydrating an aqueous macromolecule solution and crosslinking the dehydrated macromolecules with a crosslinking agent while in a liquid phase or with heat. Preferably, the dehydrating agent is a polymer mixture of polyvinylpyrrolidone and polyethylene glycol, the crosslinking reagent is glutaraldehyde, and the macromolecule is a protein, most preferably an immunoglobulin. Methods of use for research, diagnostics and therapeutics are also provided.

Claims

1. A method for making microparticles having uniform size comprising the steps of:

a) combining a solution containing a macromolecule with a solution containing both polyvinylpyrrolidone and polyethylene glycol to produce a reaction solution;

b) incubating the reaction solution at a predetermined temperature greater than room temperature for a sufficient amount of time to form microparticles; and

c) separating the microparticles from the reaction solution.

2. The method of claim 1 wherein the incubation temperature is greater than or equal to 37°

C. and less than or equal to 80°

C.

3. The method of claim 1 wherein the reaction solution is incubated for between 5 minutes and 24 hours.

4. The method of claim 1 wherein the incubation step is performed at a pH between approximately 5 and 8.

5. The method of claim 1 wherein the polyvinylpyrrolidone has a molecular weight of approximately 40,000 and the polyethylene glycol has a molecular weight of approximately 3500 and wherein the concentration of each is between 1 and 40 g/100 ml.

6. The method of claim 1 wherein the macromolecule is selected from the group consisting of a protein, carbohydrate, polysaccharide, nucleic acid molecule, virus, virus particle, pharmaceutical drug, and mixtures thereof.

7. The method of claim 1 wherein the reaction solution of step a) further comprises a crosslinking agent.

8. The method of claim 7 further comprising the step of washing the microparticles with a buffer. which contains a quenching reagent.

9. The method of claim 7 wherein the crosslinking agent is selected from the group consisting of dialdehydes, amines, multivalent ions, N-substituted maleimides, bifunctional alkyl halides, aryl halides, isocyanates, aliphatic or aromatic dicarboxylic acids, aliphatic or aromatic disulphonic acids, bifunctional imidoesters, and vinylsulphones.

10. Microparticles prepared by the method of

a) combining a solution containing a macromolecule with a solution containing both polyvinylpyrrolidone and polyethylene glycol to produce a reaction solution;

b) incubating the reaction solution at a predetermined temperature greater than room temperature for a sufficient amount of time to form microparticles; and

c) separating the microparticles from the reaction solution.

11. The microparticles of claim 10 wherein the microparticles have a size between 1 and 10 microns.

12. The microparticles of claim 10 wherein the incubation temperature is greater than or equal to 37°

C. and less than or equal to 80°

C.

13. The microparticles of claim 10 wherein the reaction solution is incubated for between 5 minutes and 24 hours.

14. The microparticles of claim 10 wherein the incubation step is performed at a pH between approximately 5 and 8.

15. The microparticles of claim 10 wherein the polyvinylpyrrolidone has a molecular weight of approximately 40,000 and the polyethylene glycol has a molecular weight of approximately 3500 and wherein the concentration of each is between 1 and 40 g/100 ml.

16. The microparticles of claim 10 wherein the macromolecule is selected from the group consisting of a protein, carbohydrate, polysaccharide, nucleic acid molecule, virus, virus particle, pharmaceutical drug, and mixtures thereof.

17. The microparticles of claim 10 wherein the reaction solution of step a) further comprises a crosslinking agent.

18. The microparticles of claim 17 wherein the crosslinking agent is selected from the group consisting of dialdehydes, amines, multivalent ions, N-substituted maleimides, bifunctional alkyl halides, aryl halides, isocyanates, aliphatic or aromatic dicarboxylic acids, aliphatic or aromatic disulphonic acids, bifunctional imidoesters, and vinylsulphones.